GlassScriptPhysician profile
Janki Patel
NPI 1669129839
$1,819.16
in general payments reported to CMS, 2019-2025
22 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $460 · 2023: $342 · 2024: $561 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $491.93 | 2023-2025 | Lifevest |
| Glaxosmithkline, LLC. | $264.35 | 2022-2024 | Arexvy, Nucala |
| Novo Nordisk INC | $166.34 | 2022-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $143.42 | 2022 | |
| Merck Sharp & Dohme LLC | $119.72 | 2023-2025 | Verquvo |
| Napo Pharmaceuticals INC | $115.72 | 2025 | Mytesi |
| Bayer Healthcare Pharmaceuticals INC. | $102.11 | 2022-2025 | |
| Exact Sciences Corporation | $78.26 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Medtronic, INC. | $61.17 | 2023-2025 | Aurora Ev-Icd Mri Surescan, Azure Xt Dr Mri Surescan |
| Irhythm Technologies, INC. | $32.83 | 2024 | Zio Xt Patch, Zio Monitor |
| Vifor Pharma, INC. | $29.76 | 2024-2025 | Veltassa |
| Kiniksa Pharmaceuticals, LTD. | $29.56 | 2022-2023 | Arcalyst |
| Stryker Corporation | $26.24 | 2024 | Prostep Mica, Easyfuse |
| E.R. Squibb & Sons, L.L.C. | $22.28 | 2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $21.06 | 2024 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.10 | 2025 | |
| United Therapeutics Corporation | $16.99 | 2023 | Tyvaso |
| Calliditas Therapeutics US INC. | $16.40 | 2024 | |
| Dexcom, INC. | $15.94 | 2023 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $15.63 | 2025 | Alvesco |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.59 | 2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $14.76 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janki Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.